Over the past years considerable effort has been directed toward identification of genes involved in cancer. We know now that mutations in more than 1% of human genes (out of ~20,000-25,000 genes in human genome) could play a role in cancer. 1 Major advances have been made in understanding the processes involved in cancer progression. Much of this knowledge has come from the study of three related genes (Hras, Kras and Nras), a family of nearly ubiquitously expressed small GTPases that regulate cell growth, proliferation and differentiation. 2 Overall, 30% of all human tumors carry mutations in ras genes, and one of the strongest correlations between cancer and ras occurs in pancreatic ductal adenocarcinoma, which has Kras mutations in 80-90% of cases.
It has been traditionally accepted that in the course of cellular differentiation, stem cells transition to becoming progenitor cells that are irrevocably committed to terminal differentiation. However, recent evidence indicates that the functional state of mature, differentiated cells is not as stable as it was thought to be. With the advent of iPS cells and lineage reprogramming technologies it has become possible to reveal that fully differentiated cells retain a high degree of phenotypic plasticity. Cancer cells are usually less well differentiated than the normal cells from which they arose. In fact, evidence derived from mouse cancer models indicates that oncogenic ras can accelerate tumor progression by imposing on cells an immature stem-like state in which differentiation is inhibited. 3 Recent evidence also suggests that the plasticity of cancer cells themselves allows more differentiated cells to spontaneously dedifferentiate into less differentiated cells, and this produces a more aggressive tumor phenotype. 4 The unifying theme underlying these studies is that carcinogenesis and cellular plasticity are tightly intertwined, since only some cell types possess the necessary plasticity to allow malignant transformation to take place, and only some oncogenes have, in the right cellular context, the requisite transforming capacity. Viewed in this light, a cancer cell of origin is a specific cell type that can progress to a tumor due to a permissive signaling context, resulting from a set of particular genetic, epigenetic or transcriptional alterations. Accordingly, cancer can be viewed as the outcome of reprogramming gone awry rather than a purely mutation-driven process. Resolving these distinctions might have important implications, as some genes involved in tumor initiation could prove to be dispensable for tumor progression and, thus, pose poor therapeutic targets, while applying reprogramming research to cancer might yield novel treatment options. 5 Recent evidence of pathological plasticity associated with oncogenic transformation has prompted us to ascertain whether genome reprogramming plays a causal role in cancer. 6 We used a welldefined system of primary p53-null mouse cells to show that endogenous expression of oncogenic KrasG12D provides a comprehensive view of tumor evolution similar to that seen in human invasive and metastatic disease. We found that regardless of the origin of cells (primary MEFs or pancreatic epithelial cells), the initiation and maintenance of the transformed state is a complex process, comprising separable stages. While the initial stage of transformation, i.e., induction of morphological changes, appears to be rapid and uniform, the acquisition of malignant properties by KrasG12D-expressing cells bears all the characteristics of a time-dependent stochastic process. Our data imply that the evolutionary relationship between premalignant and malignant cells expressing oncogenic ras represents the outcome of alterations that accumulate over time rather than one single event. This, in turn, implies that while the presence of KrasG12D mutation renders p53-null cells susceptible to transformation, other cooperatively acting genetic or epigenetic switches are needed to convert the cells to malignancy. Importantly, KrasG12D-induced malignant transformation follows the accepted definition of reprogramming kinetics of normal somatic cells, i.e., a long latency in the appearance of transformed cells in culture, stochastic nature of the process, direct phenotypic conversion occurring in many cells at once, all in the absence of new discernible mutations. We provide evidence that oncogene-induced reprogramming (dedifferentiation) is an important early step in acquisition of malignancy and cancer initiation. We further demonstrate that the conversion of precancerous to cancerous cells is determined by oncogenic ras-induced transcription factors, most notably Myc. 6 One standing problem in the therapy of cancer is metastatic disease. For instance, almost all patients who have pancreatic cancer develop distant metastases. However, little is known about the mechanisms that underlie metastasis of pancreatic cancer, and even less is known about the identity of metastasizing cancer cells. To overcome these limitations, we have developed a genetically tractable model system to investigate the origins and evolution of metastatic pancreatic cancer cells. 6 We showed that metastatic conversion of KrasG12D-expressing cells that exhibit different degrees of differentiation and malignancy can be reconstructed in cell culture, and Myc controls reprogramming and generation of self-renewing metastatic cancer cells. Collectively, our results support a model wherein non-stem cancer cells have the potential to dedifferentiate and acquire stem cell properties as a direct consequence of oncogene-induced plasticity. Moreover, the disturbance in the normally existing dynamic equilibrium between cancer stem cells and non-stem cancer cells allows the formation of cancer stem cells with high metastatic capacity at any time during cancer progression.
